MSInsight

MSInsight is a French health-tech company founded in 2022, focused on precision cancer diagnostics through advanced biomarker detection, particularly microsatellite instability (MSI). Established by a team of physicians, biologists, and engineers from Paris hospitals and academic institutions, the company leverages over 20 years of research to enhance cancer care with innovative diagnostic solutions. The flagship product, MSIcare, is an AI-powered bioinformatics software that utilizes next-generation sequencing (NGS) data to detect MSI in solid tumors and liquid biopsies. This critical biomarker helps determine patient responses to specific treatments, especially immune checkpoint inhibitors. MSIcare offers diagnostic, prognostic, and theranostic insights, enabling healthcare providers to create personalized cancer treatment plans. MSInsight also provides expert data analysis services to support clinicians with actionable genomic information, aiming to lead in MSI diagnostics and advance precision oncology. With recent seed funding of €1.6 million, MSInsight is accelerating the development and regulatory approval of MSIcare, targeting European markets with plans for global expansion.

• Employees 11
• Founded 2022